WEIS MARKETS, INC (WMK): what the price assumes

In the published model solve dated 2026-Q2, anchored at $71.20, WEIS MARKETS, INC (WMK) is priced for -4.2% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/WMK

Headline

FieldValue
TickerWMK
CompanyWEIS MARKETS, INC
Current price$71.20/sh
CompositionGrocery 81% / Pharmacy 14% / Fuel 5% / Manufacturing 0%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)0.9%
Operating margin today2.5%
Margin compression (value-band)-1.6pp
Implied growth-4.2%
Multiple paid14x operating income

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7.8% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history-0.32σ
cohort percentile (of 69 peers)17

Valuation X-Ray

The price is justified by relative-multiple; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.87x5expensive
Earnings1.64x3expensive
Relative0.97x5justifies
Growth1.32x3expensive

Families that justify the price: Relative Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.2%); the inversion above states its own rate.

Per-Model Detail (n=16)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$33.382.13xyesFCF base $0.0B, growth 5% (input: historical growth), terminal g 4.0%, WACC 7.2%, 6yr projection
DCF Exit MultipleGrowth$62.131.15xyesExit EV/EBITDA: 11.6x / 13.6x / 15.6x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$83.070.86xyesP/E 22x (static sector reference · 2026-04), scenarios: 18.4x / 22.0x / 25.6x (bear / base = reference held flat / bull), EV/EBITDA 14x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$43.501.64xyesBV/sh $56.02, ROE (TTM) 7.2%, ke 9.3%
Two-Stage Excess ReturnAsset$38.091.87xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$53.751.32xyesRev $5.1B, growth 5% (input: historical growth; tapered), Terminal P/S: 0.3x / 0.3x / 0.4x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$48.121.48xyesEPS $4.01, growth 7% (input: historical EPS growth), PEG=2.52 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$33.832.10xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.12B × (1−25%) / WACC 7.2% → EPV (no growth)
Residual IncomeAsset$37.301.91xyesBV $56.02 + 5yr PV of (ROE (TTM) 7.2% − Kₑ 9.3%) × BV; BV grows 4.7%/yr
Graham NumberAsset$71.091.00xyes√(22.5 × EPS $4.01 × BVPS $56.02) — Graham's conservative floor
EV/EBITDA RelativeRelative$73.520.97xyesEBITDA $0.16B × sector EV/EBITDA 14.0x
FCF YieldEarnings$1.2656.51xyesFCF $39.1M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarningsno
Ben Graham FormulaEarnings$75.700.94xyesEPS $4.01 × (8.5 + 2×7.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$9.477.52xyesBV $56.02 × (ROIC 1.2% / WACC 7.2%)
P/Sales SectorRelative$409.730.17xyesRevenue $5.07B × sector P/S 2.0x
PEG Fair ValueRelative$42.181.69xyesEPS $4.01 × (PEG 1.5 × growth 7.0% (input: historical EPS growth)) → PE 10.5x
Earnings YieldEarnings$43.351.64xyesEPS $4.01 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Retail (whole company)operatingenterprise4.9B reported-currencywithheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net cash$208.1m
Net debt / NOPAT (after-tax)-2.21x (net cash)
Net debt / operating income (pre-tax)-1.65x (net cash)
Interest coverage2529.0x
Share count CAGR (buyback)-2.1%
Burning cashno

Bullet Takeaways

Bull Case

The counterintuitive number for Weis Markets is the balance sheet, not the income statement. This is a regional grocer with razor-thin operating margins near 2.5 percent, the kind of business investors assume has no cushion, yet it carries a book value of about 55.39 dollars per share and almost no debt, with the cost of debt reading effectively zero. A 77-dollar stock backed by 55 dollars of mostly tangible, real-estate-heavy book value, much of it owned stores and distribution assets, is a very different risk profile than a leveraged retailer. The thin margin is the business; the fortress balance sheet is the protection, and the two together mean Weis can absorb competitive pressure that would sink a more leveraged peer.

The recent earnings show the model can still produce real operating leverage when sales cooperate. First-quarter 2026 revenue rose 4.6 percent to 1.26 billion dollars, comparable-store sales excluding fuel grew 1.2 percent, and net income jumped 42.5 percent to 27.85 million dollars, with EPS rising to 1.13 dollars from 0.73. On a 2.5 percent margin, a modest revenue gain and disciplined cost control flow through to a large percentage change in profit, which is the upside of operating a low-margin, high-volume model when conditions are favorable. The dividend, at 0.34 dollars a quarter, is comfortably covered and reflects a long history of consistent payment.

The valuation is undemanding for what it is. The price sits within range on the engine's read, justified by the peer-multiple frame, and the inversion implies only about 3.2 percent annual operating growth embedded in the price. For a defensive consumer-staple business selling food that customers buy in every economic environment, a low-single-digit growth assumption is a low bar. Weis is family-influenced, conservatively run, debt-free, and trading near a sensible multiple of normalized earnings with an asset floor well below the price. The bull case is not excitement; it is a durable, recession-resistant cash generator bought at a reasonable price, with the balance sheet doing the work of limiting downside.

Bear Case

The structural truth a Weis holder would rather not face is that this is a slowly shrinking competitive position, not a stable one, and the recent earnings jump does not change the trajectory. The retail food industry is intensely price competitive, as the company itself acknowledges, warning that the competition it encounters may negatively impact its financial condition and results (FY2025 10-K, accession 0000105418-26-000024). The longer arc is the tell: operating income fell from roughly 105 million dollars at 4 percent margins in 2010 to about 84 million dollars at 2.4 percent margins by 2019, despite acquisitions and heavy reinvestment, because Walmart supercenters, Aldi's expansion, and e-commerce grocery steadily compressed both margins and traffic. Weis operates in a slow-growth, aging-demographic region of Pennsylvania that compounds the squeeze. A 42 percent quarterly earnings jump against that backdrop is a favorable quarter, not a reversal of a fifteen-year erosion.

The profitability is also lower-quality than it appears, and that is the second hard fact. Return on equity is just 7.4 percent, well below the roughly 9 percent cost of equity, which means that on its enormous book-value base Weis is not currently earning its cost of capital. A debt-free balance sheet is a virtue, but holding 55 dollars of book value per share while earning a sub-cost-of-equity return on it is also a form of value erosion: the capital would compound faster almost anywhere else. The asset and earnings-power valuation frames both read the stock as expensive precisely because the returns on those assets are weak.

The quality concern is sharpened by an accounting issue. Weis disclosed a roughly 22-million-dollar meat-plant inventory misstatement spanning 2022 through 2025, which suggests recent profitability may have been overstated and raises the question of how clean the reported earnings really are. Pharmacy, one of the higher-margin departments, faces a structural headwind: Q1 pharmacy revenue was hit by about 7.48 million dollars from Inflation Reduction Act Medicare maximum-fair-price provisions, a policy drag that will persist. Put together, the bear case is a low-return, slow-erosion grocer in a hard region, with an accounting blemish and a regulatory drag on its best department, trading above the value its weak returns on assets actually justify.

Valuation

Weis Markets is a low-margin, asset-heavy grocer, and its valuation X-ray splits between a high book value and weak returns on that book. The asset-based excess-return frames land around 40 to 45 dollars, below the 77-dollar price, because while book value per share is a substantial 55.39 dollars, the trailing ROE of 7.4 percent is below the cost of equity, so the excess-return math actually discounts the book rather than adding to it. The zero-growth earnings-power frame lands near 33 dollars, also well below the price, reflecting the thin operating margin. What holds the price up is the relative-multiple frame: at a sector P/E near 22 times, the relative-valuation read lands around 84 dollars, above the price, and the exit-multiple DCF lands near 64 dollars.

Inverting the price gives a gentler read. At the current level the market is paying about 17 times company-wide operating income, implying only about 3.2 percent annual operating growth for five years. For a defensive grocer that is a modest assumption, and each one-percentage-point change in the cost of capital moves the implied growth by about 7 points, so treat it directionally. The point is the price does not require much growth, which is appropriate for the business.

The honest synthesis is that Weis is a balance-sheet story trading at a peer multiple its returns do not quite earn. An investor is paying about 77 dollars for 55 dollars of book value that generates a sub-cost-of-equity return, plus a defensive, debt-free earnings stream and a covered dividend. The asset floor limits downside, and the low implied growth is achievable.

Catalysts

The near-term catalyst is whether the Q1 2026 momentum is durable or a single favorable quarter. Comparable-store sales excluding fuel grew 1.2 percent, so the trend in comps over the next quarters is the cleanest read on whether Weis is holding its ground against discount competition or merely benefiting from food inflation. Cost discipline and any margin recovery would show whether the 42.5 percent net-income jump can be sustained on a thin operating base.

The regulatory and structural catalysts are slower but real. The Inflation Reduction Act Medicare maximum-fair-price provisions cost pharmacy roughly 7.48 million dollars in the quarter, and the trajectory of that drug-pricing drag will weigh on one of the higher-margin departments. Resolution and any further disclosure around the roughly 22-million-dollar meat-plant inventory misstatement is a quality catalyst worth watching, because it bears on the reliability of recent earnings. Capital allocation is the steady signal: the dividend, set at 0.34 dollars a quarter, and any use of the debt-free balance sheet for buybacks, store investment, or acquisitions, show how management deploys a strong balance sheet against a structurally challenged backdrop.

Sources: Weis Markets posts higher Q1 2026 sales, earnings and comps, stocktitan.net; Weis Markets reports first quarter 2026 results, prnewswire.com; Weis Markets Q1 revenue rises 4.6 percent, EPS hits 1.13, stocktitan.net; Weis Markets revenue growth and EPS pressure, simplywall.st.

Peer Cohorts (Per Segment, With Filing Citations)

Retail (whole company) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive WMK report on boothcheck